Hearing loss in children treated for multidrug-resistant tuberculosis.

Seddon, JA; Thee, S; Jacobs, K; Ebrahim, A; Hesseling, AC; Schaaf, HS; (2012) Hearing loss in children treated for multidrug-resistant tuberculosis. The Journal of infection. ISSN 0163-4453 DOI: https://doi.org/10.1016/j.jinf.2012.09.002

Full text not available from this repository.


: OBJECTIVE: The aminoglycosides and polypeptides are vital drugs for the management of multidrug-resistant (MDR) tuberculosis (TB). Both classes of drug cause hearing loss. We aimed to determine the extent of hearing loss in children treated for MDR-TB. METHODS: In this retrospective study, children (<15 years) admitted to Brooklyn Chest Hospital, Cape Town, South Africa, from January 2009 until December 2010, were included if treated for MDR-TB with injectable drugs. Hearing was assessed and classified using audiometry and otoacoustic emissions. RESULTS: Ninety-four children were included (median age: 43 months). Of 93 tested, 28 (30%) were HIV-infected. Twenty-three (24%) children had hearing loss. Culture-confirmed, as opposed to presumed, diagnosis of TB was a risk factor for hearing loss (OR: 4.12; 95%CI: 1.13-15.0; p=0.02). Seven of 11 (64%) children classified as having hearing loss using audiometry had progression of hearing loss after finishing the injectable drug. CONCLUSIONS: Hearing loss is common in children treated for MDR-TB. Alternative drugs are required for the treatment of paediatric MDR-TB.

Item Type: Article
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Clinical Research
PubMed ID: 22960077
Web of Science ID: 315860500004
URI: http://researchonline.lshtm.ac.uk/id/eprint/251138


Download activity - last 12 months
Downloads since deposit
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item